



Impact of Vaccine Vial Monitors (VVM) in LMICs

25 Years of Supporting Vaccine Rollout with Tailored VVM Types; ready for Regional Vaccine Production

October 17, 2024

Jon Pearman


Supranational Consultant Zebra Temptime



What are VVMs?

Heat-sensitive sensors attached to vaccine vials
Change color based on heat exposure, cumulatively and irreversibly

Their Purpose:
Indicate if vaccines were exposed to excessive heat



Please have a good look at WHO's info graphic on how to use the VVM - there will be a quiz in the second half of this presentation

The Need for VVMs in Global Vaccination Efforts

1974 during a Tanzanian Measles Campaign, John Lloyd & James Cheyne observed unexpected measles disease, in both vaccinated and un-vaccinated children. The suspect was heat damaged vaccine



- John Lloyd (and others) became champions in finding a solution
- 22 years later (1996) the first ever vaccines were delivered with VVMs
- The development was led by WHO, PATH and Temptime, now Zebra
- The development is a case study in innovation in public health

The Impact of VVM


The VVM was a Success:

- Help ensured vaccine potency in remote areas
- Allowed campaigns in extreme conditions
- Enable vaccines to be stored longer
- Reduced vaccine wastage from unnecessary discarding (Bhutan study)


In 2001, WHO mandated VVM and in 2003 Gavi followed suit

Vaccine wastage rates before and after implementation of VVM and open-vial policy
(brick color markings correspond to wastage)

Baseline vaccine wastage rates




Vaccine wastage rates with VVM and open-vial policy



Bhutan study: Nov-1988, PATH, funded by WHO

VVM mandated for all WHO PQd vaccine programs



Vaccines have specific (inherent) stability profiles and VVMs have to be made available in different types (or categories), to match them

Look at the text (outside or inside reference ring) there is number



VVM2

For highly heat labile vaccines, reaches discard point in 2 days at 37°C




VVM14

Medium stable vaccines , reaches discard point in 14 days at 37°C

And so on....

WHO PQd vaccines by VVM Type



VVM2 is used on Highly heat labile OPV, as well as 1 Rota, several Flu and the latest Dengue vaccine.



tOPV



mOPV1



bOPV1&3




nOPV2





Dengue (Takeda)


WHO PQd vaccines by VVM Type



VVM14 is found on medium stability DTP containing vaccines including penta, the Iyo vaccines: JE, YF & BCG, Dengue, MR containing and the 2 new Malaria vaccines.




WHO PQd vaccines by VVM Type



VVM30, is used on high stability BCG, DT, TT, HepB, HPV, all the conjugate vaccines, Hib, Pneumo, Men5/MenA, Typhoid as well as Cholera, and Rota



WHO PQd vaccines by VVM Type



VVM7: used for Moderate stability vaccines IPV, Flu and Rota. One of the new Hexavalent vaccines also has it.



Inactivated Polio Vaccines




Rota




New Hexavalent

WHO PQd vaccines by VVM Type



VVM11, made for one IPV vaccine and also the other Hexavalent just prequalified in 2024.



IPV



Hexavalent

What about the future for VVMs:

New Technologies:

- VVMs for mRNA vaccines (heat labile vaccines needing UCC storage)
- VVMs for heat stable vaccines, to be used in the last mile without cool packs, in controlled temperature chain – called VVM+
- Digital monitoring systems (making use of the VVM chemistry impregnated into bar codes)

VVM1
VVM0.5
VVM0.25




Ready to support regional vaccine manufacturers

VVM is applied to caps, vials, ampoules, and tubes (plastic)

- Provide engineering support to fill finish lines
- Provide training on receipt and storage of VVM shipments
- Facilitate procurement of qualified densitometers used for Quality Control
- Verify vaccine label artwork allow for VVM positioning
- Consult on labeler equipment parameters to ensure VVM application can be performed at speed



- Welcome to our New Jersey, USA facility for business reviews and Quality audits
- We stand ready to support regional vaccine producers



Conclusion

- VVMs facilitated vaccine rollouts
- Reduced wastage and expanded coverage
- Supporting future vaccine introductions